Clinical trials: Cognitive Assessment
Cognitive Performance
Evaluation of the Effects of Berry Leaf Extract on Cognitive Processing in Healthy Elderly Adults
This study aims to explore the positive effect of a dietary supplement composed of berry leaf extract on the cognitive performance and regulation of stress, mood, sleep and fatigue in healthy elderly adults with self-reported…
- Trial name
- SLE (NCT06819163)
- Testing
- Berry leaf extract
- Where
- Belgium
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Seppic
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Post-Operative Confusion
Braindex Cerebral Tissue Oxygen Saturation (SctO2) Measurement Algorithm Assessment and Improvement
The objective of this clinical trial is to optimize Braindex brain tissue oxygen saturation (SctO2) measurement algorithm compared to a mixed reference value of jugular venous and systemic arterial saturation, during proven…
- Trial name
- POC-SctO2 (NCT05897060)
- Testing
- Venus Jugular O2 Saturation optical fiber
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Braindex
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02342041
- Testing
- SUVN-G3031
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to…
- Trial name
- NCT02094729
- Testing
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Memory Deficits, Cognitive Change
An Exploratory Investigation of a Supplement to Promote Brain Health
Providing a combination of synergistic dietary supplements, such as vitamins B6, B12, and folate, as well as curcumin, lemon balm, and American ginseng is hypothesized to promote brain health and aid with brain fog, mental…
- Conditions
- Memory Deficits, Cognitive Change, Stress
- Trial name
- NCT05520424
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Parable
Fibromyalgia
A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make decisions or problem solve.
- Trial name
- NCT00752505
- Testing
- Esreboxetine
- Where
- 7 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Pfizer
Opioid-use Disorder
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC)…
- Trial name
- NCT04948307
- Testing
- OXD01 digital therapy, Standard of Care
- Where
- 21 sites in United States
- Volunteers
- 437 people
- Sponsor
- Orexo AB
Dietary Supplement, Cognition
Nutritional Supplement's Effects on Cognition
This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.
- Conditions
- Dietary Supplement, Cognition, Healthy
- Trial name
- NCT05941949
- Testing
- Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E
- Where
- Australia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Healthy Volunteers
Reliability and Validity of Online Cognitive Assessments
The purpose of this study is to evaluate the concurrent validity (correlation coefficient of scores at 1 time point) between the Brain Performance Test (BPT, Lumos Labs, Inc.) and a validated third party computerized assessment.
- Trial name
- NCT02382393
- Testing
- Brain Performance Test (BPT, Lumos Labs, Inc), Computerized Assessment
- Where
- United States
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Lumos Labs, Inc.
Alzheimer Disease
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease.
- Trial name
- NCT01872598
- Testing
- Masitinib, Standard of care
- Where
- 6 sites in Bulgaria, Greece and 4 more
- Volunteers
- 721 people
- Sponsor
- AB Science
Vascular Cognitive Impairment
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease
- Trial name
- NCT05050604
- Testing
- Choline Alfoscerate 400mg
- Where
- South Korea
- Volunteers
- 418 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Cognitive Change
CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women
The investigators propose to conduct the present study in order to primarily assess the effects of CMI-168 in neurocognition enhancement.
- Trial name
- NCT03612752
- Testing
- CMI-168
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Cerebos Pacific Limited
Insomnia
WELT-REST: WELT Randomized Evaluation of Sleep Therapy
The goal of this clinical trial is to learn whether the SleepQ mobile app can help reduce insomnia symptoms in adults diagnosed with insomnia.
- Trial name
- WELT-REST (NCT07289217)
- Testing
- SleepQ Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- WELT corp
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in PACC5 between baseline and +12 month follow up across all four Arms, as…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-FUTURE (NCT04846426)
- Where
- 4 sites in United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Primary Biliary Cholangitis (PBC)
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone…
- Trial name
- NCT07304843
- Testing
- golexanolone
- Where
- 38 sites in Germany, Greece and 6 more
- Volunteers
- 207 people
- Sponsor
- Umecrine Cognition AB